111 Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top 19 shareholders own 65.76% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
21.7%	Junling Liu	18,565,567	US$11.4m	0%	no data
21.1%	Gang Yu	18,029,212	US$11.0m	0%	no data
9.25%	ClearVue Partners	7,924,132	US$4.8m	0%	no data
5.07%	First Pharmacia International	4,345,281	US$2.7m	0%	no data
4.23%	6 Dimensions Capital Limited	3,622,947	US$2.2m	0%	0.64%
1.67%	Zhi Yan	1,431,186	US$875.2k	0%	no data
1.26%	Zhenxiang Huo	1,077,817	US$659.1k	0%	no data
1.11%	Beijing ChinaEquity Equity Investment Management Co., Ltd.	949,751	US$580.8k	0%	1.03%
0.16%	Renaissance Technologies LLC	134,247	US$82.1k	19.7%	no data
0.074%	NFS Capital AG	63,428	US$38.8k	0%	0.01%
0.06%	Morgan Stanley, Investment Banking and Brokerage Investments	51,381	US$31.4k	9.6%	no data
0.049%	Citadel Advisors LLC	41,927	US$25.6k	20.7%	no data
0.039%	Geode Capital Management, LLC	33,100	US$20.2k	0%	no data
0.036%	XTX Holdings Limited, Asset Management Arm	31,123	US$19.0k	0%	no data
0.018%	Hudson River Trading LLC, Asset Management Arm	15,028	US$9.2k	0%	no data
0.012%	Rhumbline Advisers Ltd Partnership	10,220	US$6.2k	0%	no data
0.0027%	UBS Asset Management AG	2,303	US$1.4k	-87.7%	no data
0.00082%	JPMorgan Chase & Co, Brokerage and Securities Investments	700	US$429.5	-99.9%	no data
0.00034%	Eaton Vance Management	287	US$178.1	0%	no data